Studies patient journeys and outcomes in transthyretin amyloidosis
Collects real-world records of people with ATTR amyloidosis, observing their care and outcomes.
Plain-language title generated from the registry record
Registry title: OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis
Key facts
- Where
- Eden Prairie, United StatesSee the site
Where in United States
- Eden PrairieEden Prairie, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- AstraZeneca
- Trial code
- NCT06355934
- Record updated
- 9 September 2026
- Original description
The overall aim of this observational study is to generate real-world evidence on the pre- and post-diagnosis disease journeys, including baseline characteristics, treatment patterns and selected clinical, economic, and humanistic outcomes (for example Health Related Quality of Life (HRQoL), Neuropathy impairment score, activities of daily living (ADL) assessments) in patients with ATTR amyloidosis, and to better understand how the disease is presented.Read full original descriptionShow less
OverTTuRe: An Observational Multi-Country Study Collecting Real-World Secondary Data on the Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis
The overall aim of this observational study is to generate real-world evidence on the pre- and post-diagnosis disease journeys, including baseline characteristics, treatment patterns and selected clinical, economic, and humanistic outcomes (for example Health Related Quality of Life (HRQoL), Neuropathy impairment score, activities of daily living (ADL) assessments) in patients with ATTR amyloidosis, and to better understand how the disease is presented.
Inclusion: Patients aged >18 years at study index date AND; A reported diagnosis code for amyloidosis OR; A claim for ATTR-specific treatment OR; A positive biopsy for amyloidosis and positive immunostaining result of biopsy for ATTR.
Exclusion: At least one claim/procedure code for stem cell transplant or at least two claims/procedure codes for chemotherapy and autoimmune disease drugs which may represent AL (primary) or AA (secondary) amyloidosis treatments; Evidence of primary (AL) and secondary (AA) amyloidosis AND/OR.